



WELCOME MESSAGE

Dear MSO Members,

The MSO have now had our own newsletter, the MSO Express, produced quarterly this past year. We hope you have found it informative and useful as it this forms one important aspect of the MSO's communication channels. Do provide feedback to the committee if you would like to see anything more in the future issues as we are always planning to broaden the scope of this newsletter.

The MSO are continuing their efforts of increasing public awareness of the dangers of unlicensed eye-care products. We have also made contact with MIMS Medica to try and ensure published advertisements are moderated to a certain extent as a recent ad for Neo-Deca appears to promote the unsolicited use of steroid drops for trivial purposes without raising their readers' awareness of the dangers of such and the complications of which many of us have seen.

In the spirit of cooperation with MOH for the greater good of the community, the MSO have recently successfully relocated the fundus

camera donated to us, to Klinik Kesihatan Jeram, where we are certain that it will be more fully-utilised. The committee are also in full swing for preparation for World Sight Day 2017. This year we are looking forward to a collaboration with Yayasan Diraja Sultan Mizan (YDSM) and The Association of Malaysian Optometrists (AMO), with whom we are planning to screen over 1000 needy patients in Kuala Terengganu on October 14th and 15th.


It is going to be a busy few months ahead as the APVRS is around the corner on 8th - 10th December then the 33rd MSJOC to be held on 16th - 18th March 2018 at Malacca in collaboration with the SSO and for the first time, also the ASEAN Ophthalmology Society (AOS). Do ensure to mark your calendars to ensure you don't miss these events as we have an exciting line-up of topics by international speakers and social events being planned at both events.

With the minimum compulsory requirement for collecting CPD points drawing closer, do make sure you attend these international conferences to get more bang-for-buck in



addition to taking advantage of the early bird rates. As always, trainees who are also MMA members can apply to claim most of their registration fees reimbursed by our dedicated MMA Foundation Eye Fund.

Do log on to your own personal membership portal on the MSO website where you can register your details, pay for your membership and register for any MSO-organised conferences. As always, this is your society and the MSO needs your support to carry on its activities; by its members, for its members.



DR. MANO SHUNMUGAM

Editor, MSO Express
Honorary Secretary, MSO

THE POWER OF LUMIGAN

LUMIGAN[®]
Bimatoprost ophthalmic solution 0.01%
Because every mmHg counts

Abridged prescribing information:
Solution containing 0.1mg/ml Bimatoprost.
Dosage & administration: One drop in the affected eye(s) once daily in the evening. Indications & Usage: LUMIGAN[®] 0.01 is a prostaglandin analog indicated for the reduction of elevated intraocular pressure in patients with chronic open angle glaucoma and ocular hypertension.
Contraindications: Hypersensitivity to the active substance or to any of the excipients. LUMIGAN[®] 0.01 is contraindicated in patients who have had a suspected previous adverse reaction to benzalkonium chloride that has led to discontinuation. Warnings and Precautions for use: Pigmentation of the iris, periosteal tissue (eyelid) and eyelashes can occur. Iris pigmentation is likely to be permanent. Gradual change to eyelashes including increased length, thickness and number of lashes. Usually reversible. Adverse reactions: Most common adverse reaction is conjunctival hyperemia (28%). Clinical Pharmacology: Mechanism of action: Bimatoprost, a prostaglandin analog, is a synthetic structural analog of prostaglandin with ocular hypotensive activity. It selectively mimics the effects of naturally occurring substances, prostamides. Bimatoprost is believed to lower intraocular pressure (IOP) in humans by increasing outflow of aqueous humor through both the trabecular meshwork and uveoscleral routes. Elevated IOP presents a major risk factor for glaucomatous field loss. The higher the level of IOP, the greater the likelihood of optic nerve damage and visual field loss. Please refer to package insert for more information.

Allergan Malaysia Sdn Bhd (031025-D)
Level 9-12, Block A, P.O. No. 23, Jalan Barat,
Seksyen 8, 4005 Petaling Jaya, Selangor, D.F.
Tel: +603 7507 3885 Fax: +603 7507 3141

Allergan Singapore Pte Ltd
27 North Bridge Road, Singapore Business City,
West Building, #07-25, Singapore 178437
Tel: +65 6347 7077 Fax: +65 6276 8252

SGM100292018a
Date of preparation: Aug 2017